Griffith Joseph H. IV sold $63K of MASS

Griffith Joseph H. IV (Chief Financial Officer) sold 6,940 shares of 908 Devices Inc. (MASS) at $9.03 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Griffith Joseph H. IV
Published May 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MASS
Neutral
medium confidence
Mentioned
$MASS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MASSNeutralLow
01

Why it matters

The key trading takeaway is sentiment/positioning rather than fundamentals, given the lack of new operating or strategic information.

02

Market read

Traders may briefly reassess near-term sentiment due to insider selling, but the 10b5-1 structure limits fundamental interpretation.

03

What to watch

Insider sales can be driven by diversification/tax planning; the filing doesn’t provide intent or changes in business outlook.

Relevance 6/10Novelty 3/10Timing: Filed after-hours on 2026-05-29, reflecting a 2026-05-28 sale.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CFO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$MASSNeutralMedium confidence
Context

MASS CFO Griffith Joseph H. IV sold 6,940 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Limited/short-lived downside pressure possible; no clear directional catalyst from the filing alone.

Evidence & confidence

The disclosure is an ownership-change datapoint (not earnings/guidance/M&A). The presence of a 10b5-1 plan reduces interpretive weight, though traders may still react to insider selling headlines.

Market effects

No sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because it’s a pre-arranged 10b5-1 plan, the sale may be purely mechanical and not a bearish signal.

Key entities

  • Griffith Joseph H. IV

    Chief Financial Officer of 908 Devices Inc. who sold shares under a pre-arranged 10b5-1 plan.

  • 908 Devices Inc.

    Company whose shares (MASS) were sold by its CFO; filing is the source of the datapoint.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MASSHigh

908 Devices Inc (MASS) (Q3 2026) Earnings Call Highlights: Record $19 Million Revenue

908 Devices Inc (MASS) reported Q3 2026 revenue of $19M, up 35% YoY, driven by FTIR products and NearLab sales. The company raised full-year revenue guidance to $68.5M-$70M. Adjusted EBITDA loss narrowed to $1.7M, but gross margin decreased to 58%. MASS shipped 300+ devices, bringing the installed base to 4,400. NearLab integration is progressing, with 100 devices sold in Q3. The company remains unprofitable, with a net loss of $4.6M and $2.4M cash burn.

$MASSMed

908 Devices Q3 2026 slides: 35% growth, raised guidance

908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.

$MASSMed

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook ​ ​ BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap

$MASSMed

908 Devices Inc. Q2 2026 Earnings Call Summary

908 Devices reported Q2 2026 revenue up 23%, driven by U.S. state and local demand for fentanyl and synthetic drug detection. VipIR saw 35+ shipments, and the NIRLAB acquisition added an AI subscription model. Full-year 2026 revenue guidance was raised to $68m-$70m. Adjusted EBITDA loss narrowed 50% YoY; recurring revenue target is 30%+.

$MASSMedAI 8/10

908 Devices Q2 Earnings Call Highlights

908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).